Previous 10 | Next 10 |
Lexicon Pharmaceuticals, Inc. ( LXRX ) has been badly pummeled this week. It has dropped from last week's close of $5.69 to $1.35 on Wednesday after Sanofi ( SNY ) terminated its collaboration with it to develop, manufacture and commercialize Zynquista for diabetes and Q2 results that re...
Lexicon Pharmaceuticals Inc. (LXRX) Q2 2019 Results Conference Call August 1, 2019 09:00 AM ET Company Participants Kimberly Lee - Head of Investor Relations and Corporate Strategy Lonnel Coats - President and Chief Executive Officer Alex Santini - Executive Vice President and Ch...
Gainers: Big 5 Sporting Goods Corporation (NASDAQ: BGFV ) +35% . Enphase Energy (NASDAQ: ENPH ) +31% . Quad/Graphics (NYSE: QUAD ) +30% . Lattice Semiconductor Corporation (NASDAQ: LSCC ) +22% . Systemax (NYSE: SYX ) +20% . Unisys Corporation (NYSE: UIS ) +21% . Lydall (NYSE: L...
Lexicon Pharmaceuticals ( LXRX ) Q2 results : Revenues: $9.7M (-29.7%); Net product revenue: $8.7M (+19.2%); Collaborative agreements: $0.9M (-85.9%); Royalties and other revenue: $0.2M (+150.0%). More news on: Lexicon Pharmaceuticals, Inc., Healthcare stocks news, Earnings...
2U (NASDAQ: TWOU ) -41% on Q2 earnings . More news on: 2U, Inc., Sigma Labs, Inc., T2 Biosystems, Inc., Stocks on the move, Read more ...
Lexicon Pharmaceuticals (NASDAQ: LXRX ): Q2 GAAP EPS of -$0.22 misses by $0.16 . Revenue of $9.7M (-29.7% Y/Y) misses by $18.82M . Shares -3.6% PM. Press Release More news on: Lexicon Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, ,
THE WOODLANDS, Texas, July 31, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results and provided a business update for the three months ended June 30, 2019. “We are pleased that recent preliminary results of three Phase 3 clini...
THE WOODLANDS, Texas, July 30, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that it has changed the date of its previously announced earnings release, conference call and webcast and will now release financial results for the second quarter of 2...
Gainers: NovaBay Pharmaceuticals (NYSEMKT: NBY ) +34% . Medley Management (NYSE: MDLY ) +33% . Pieris Pharmaceuticals (NASDAQ: PIRS ) +24% . Daxor (NYSEMKT: DXR ) +18% . Oasmia Pharmaceutical AB (NASDAQ: OASM ) +17% . Acasti Pharma (NASDAQ: ACST ) +15% . Mylan N.V. (NASDAQ: MYL...
Lexicon Pharmaceuticals (NASDAQ: LXRX ) -54% . More news on: Lexicon Pharmaceuticals, Inc., Obalon Therapeutics, Inc., Exact Sciences Corporation, Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Lexicon Pharmaceuticals Inc. Company Name:
LXRX Stock Symbol:
NASDAQ Market:
Lexicon Pharmaceuticals Inc. Website:
INPEFA ® (sotagliflozin) Net Sales of $1.6 Million in Q2 2024 Resubmitted NDA for ZYNQUISTA ™ (sotagliflozin) in Type 1 Diabetes, Launch Preparations Underway with PDUFA Goal Date of December 20, 2024 Commenced SONATA Phase 3 Study...
THE WOODLANDS, Texas, July 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its second quarter 2024 financial results on Thursday, August 1, 2024 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00...
Launch Preparations Actively Underway; Launch Planned for Early 2025 Lexicon Seeks Approval for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease THE WOODLANDS, Texas, July 16, 20...